This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
QIAGEN's TB Testing Business Gets New Exposure at Global Summit
by Zacks Equity Research
QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.
ABTPositive Net Change HOLXNegative Net Change QGENPositive Net Change RVTYPositive Net Change
biotechnology biotechs medical
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
by Zacks Equity Research
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
REGNPositive Net Change BAYRYPositive Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Roku (ROKU) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ROKUPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
by Zacks Equity Research
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
REGNPositive Net Change SNYPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
by Zacks Equity Research
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
by Zacks Equity Research
PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.
ALNYPositive Net Change PTCTPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
by Ahan Chakraborty
Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.
VRTXPositive Net Change CRSPPositive Net Change FULCPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Riot Platforms, Inc. (RIOT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RIOTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
by Zacks Equity Research
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.
ALNYPositive Net Change ANIPNegative Net Change ACADPositive Net Change SLNONegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Gains 13.5% Year to date: How to Play the Stock?
by Zacks Equity Research
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Receives $1 Billion From Starboard Value, Stock Rises
by Zacks Equity Research
PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechnology medical pharmaceuticals
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
by Zacks Equity Research
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.
ALNYPositive Net Change CPRXPositive Net Change ANIPNegative Net Change RAREPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
by Zacks Equity Research
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
CPRXPositive Net Change ANIPNegative Net Change BHVNPositive Net Change SRRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
SoFi Technologies, Inc. (SOFI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SOFIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ONCY Stock Up on Regulatory Update From Breast Cancer Program
by Zacks Equity Research
Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.
AZNPositive Net Change RHHBYPositive Net Change ONCYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
by Zacks Equity Research
EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for growth.
ALNYPositive Net Change BMYPositive Net Change EXELNegative Net Change KRYSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pacira's Exparel Receives Permanent New Product-Specific J-Code
by Zacks Equity Research
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
PCRXNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
by Zacks Equity Research
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
ANIPNegative Net Change RAREPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
by Zacks Equity Research
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
GILDNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
by Zacks Equity Research
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
BMYPositive Net Change ANIPNegative Net Change FULCPositive Net Change STTKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
by Zacks Equity Research
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
BMYPositive Net Change PRMENegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology cell-therapy medical pharmaceuticals
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
PFEPositive Net Change MRNAPositive Net Change ARCTPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
ProAssurance (PRA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PRANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
ANIPNegative Net Change KRYSNegative Net Change SAVANegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals